InvestorsHub Logo
Followers 0
Posts 752
Boards Moderated 0
Alias Born 03/29/2009

Re: None

Wednesday, 08/04/2010 4:28:52 PM

Wednesday, August 04, 2010 4:28:52 PM

Post# of 19508
Sorry if someone already posted this before, but I thought it was worth reading. This is a snipet of the transcript from Covidien's last financial call for the 3rd quarter.

Covidien Ltd. F3Q10 (Qtr End 6/30/10 Earnings Call Transcript

Rick Wise - Swanson

And just as a quick followup to that, is this something that you address to try to offset and improve over the next couple of years, you address totally internally, or does this raise the greater likelihood that you’ll try to seek some technology products externally? Thanks.

Chuck Dockendorff Covidien


Sure. We don’t comment specifically on M&A. But I think what you’ve seen in the past with pharma, what we’ve done is built up a nice clinical regulatory, scientific capability. We know have a sales force in this controlled-substance area. I think there will be other opportunities to do the kind of licensing deals that will bring in new product opportunities where we can leverage our skills in those areas I just mentioned, as well as our sales force.

I like our strategy, and I think that’s where you’ll see our strategy continue to focus from a growth standpoint.